Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T22:03:22.117Z.
Consensus retrieved: 2026-10-06T14:14:10.765Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:03:22.117Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 82cee4a6010f8650e239c44e6fa86f6cad5a1cacb0b867e980d6d40a64789328
Forward PE Ratio (N/A) = Dated Quote Price ($1.77) / Consensus Forward EPS ($-0.51)
FORWARD PE RATIO
N/A
Nautilus Biotechnolgy, Inc.
Market Cap
$225.24M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Nautilus Biotechnolgy, Inc. (NAUT) | $225.24M | N/A |
| Biodesix, Inc. (BDSX)vs › | $227.60M | N/A |
| Vogenx Inc. (VOGX)vs › | $227.91M | N/A |
| Profound Medical Corp. (PROF)vs › | $220.93M | N/A |
| MacroGenics, Inc. (MGNX)vs › | $231.37M | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $231.77M | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | N/A |
| InflaRx N.V. (IFRX)vs › | $232.72M | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | N/A |
| Utah Medical Products, Inc. (UTMD)vs › | $235.08M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.77, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.51 | $-0.70 – $-0.40 | 3 | n/m |
| 2027-12-31 | $-0.52 | $-0.71 – $-0.41 | 3 | n/m |
| 2028-12-31 | $-0.44 | $-0.48 – $-0.42 | 3 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
